CAR T-Cell Therapy: Recent Advances and Future Considerations

November 15, 2018

Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This webinar describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.

Target Audience

This activity is designed to meet the needs of oncologists, hematologists, nurses, pharmacists, physician assistants, and other health care professionals treating patients on CAR T-cell therapy.

Learning Objectives

Following this activity, participants should be able to:

  • Outline fundamental elements of chimeric antigen receptor (CAR) design and CAR T-cell therapy development
  • Summarize key studies using CD19-targeted CAR T-cell therapy in relapsed/refractory B-cell malignancies
  • Discuss preclinical and clinical strategies being developed for CAR T-cell therapy use in solid tumors
  • Identify current and emerging management strategies for CAR T-cell therapy-associated toxicities
  • Summarize recommended considerations for CAR T-cell persistence and disease surveillance
  • Outline seminal components required to establish institutional CAR T-cell therapy programs
  • Discuss current coverage/reimbursement structures and proposed reimbursement strategies for CAR T-cell therapy
Additional information
Supporters: 

This activity is supported by educational grants from Kite Pharma and Novartis.

Course summary
Available credit: 
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
10/09/2018
Course expires: 
01/13/2019
Event starts: 
11/15/2018 - 2:00pm
Event ends: 
11/15/2018 - 3:15pm
Cost:
$0.00

Lihua E. Budde, MD, PhD
City of Hope National Medical Center

Elizabeth J. Shpall, MD
The University of Texas MD Anderson Cancer Center

Joseph C. Alvarnas, MD
City of Hope National Medical Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Definitions  

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:

Joseph C. Alvarnas, MD
Elizabeth J. Shpall, MD 

The faculty listed below discloses the following relevant financial relationships:

Lihua E. Budde, MD, PhD
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau
Kite Pharma: Product/Speakers Bureau
Precision Bioscience: Scientific Advisor
ProMab Biotechnologies, Inc.: Scientific Advisor

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; CHCP Lisa G. Kimbro, MBA, CPA (Employed by NCCN until 8/10/18); Joan S. McClure, MS (Employed by NCCN until 8/1/18); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, Melinda Somasekhar, PhD (Employed by NCCN until 10/30/17)

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:

Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

Katherine Pierce
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Ndiya Ogba, PhD; Rashmi Kumar, PhD

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 hours of Category 1 credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: 0836-0000-18-131-L01-P

Available Credit

  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation

Accreditation Period

Course opens: 
10/09/2018
Course expires: 
01/13/2019

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Thursday, November 15, 2018, from 2:00 - 3:15 PM Eastern Standard Time (EST) (UTC -5).

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing